

Haematologica
HAEMATOL/2017/178798
Version 3

Ibrutinib for chronic lymphocytic leukemia: international experience
from a named patient program

Peter Hillmen, Joris Diels, Nollaig Healy, Wafae Iraqi, Johan Aschan,
and Mark Wildgust

Disclosures: JD, NH, WI, JA, and MW are employees of Janssen. PH has received research funding and speaker fees from Janssen, AbbVie, Novartis, Roche, and Gilead.

Contributions: PH, JD, NH, WI, JA and MW have all made substantial contributions to study design, data acquisition, analysis or interpretation, drafting the article, critically revising the content and final approval of the submitted version. JD performed the statistical analyses. Agreements with the study sponsor did not restrict the academic authors in the publication of these data.